Newsstand | Page 6 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Oncologists tell the backstory of informed consent

Originally Published: 03/02/2017
We want to let you in on a secret. As your oncologists, we’d like to treat you with two, or three, or four different chemotherapy drugs, each of which has distinct side effects, some of which can kill you. Or, if we were cardiothoracic surgeons, we might tell you that we need to crack your chest open to repair your damaged heart valve, and for that to happen you’ll need to undergo anesthesia from which you may never wake up. As doctors, our goal is to help you, of course, and to do no harm. But we may actually hurt you, irreversibly. Not that this happens frequently, but it might. How does...

Drug reduces acute GVHD in unrelated HSCTs

Originally Published: 02/27/2017
Vorinostat (Zolinza) combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease (GVHD) in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant (HSCT).1 In a phase II single-arm study, the cumulative incidence of grade 2-4 acute GVHD at day 100 with the vorinostat combination was 22%, which met the primary endpoint of the study (target incidence of less than 28%). The historical incidence of acute GVHD despite standard immunosuppressive prophylaxis in patients receiving HSCT is...

Aplastic Anemia Update - February 2017

Originally Published: 02/24/2017
Aplastic Anemia Update - February 2017

Advances in antiviral drug cuts infection post SCT

Originally Published: 02/23/2017
  In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has shown that a novel agent can protect against the most common viral infection that patients face after transplantation. The results represent a breakthrough in a decade-long effort to identify an effective drug for the prevention of CMV infection in transplant patients that doesn’t produce side effects that negate the benefit of the drug itself, the study authors said. The findings, from an...

Foundation Update - February 2017

Originally Published: 02/17/2017
Foundation Update Newsletter - February 2017   MDS and Inflammation Dr. Alan List is the president and CEO of Moffitt Cancer Center in Tampa, Florida. He is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. Prior to joining Moffitt in 2003, Dr. List was a professor of medicine and director of the Leukemia and Bone Marrow Transplant Program at the University of Arizona Tucson, as well as director of the Division of Translational/Clinical Research. Read Dr. List's comments on recent discoveries in inflammation as it...

Discovered: Simple way to identify GVHD risks

Originally Published: 02/09/2017
(New York, NY - February 3, 2017) --Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, according to a study published in JCI (The Journal of Clinical Investigation) Insight. This international study at 11 cancer centers examined blood samples from almost 1,300 bone marrow transplant patients and found that two proteins present in blood drawn a week after a transplant can predict whether a patient will develop a lethal...

New study hails test to weigh SCT for MDS

Originally Published: 02/09/2017
Newswise — A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research by scientists at Dana-Farber Cancer Institute and Brigham and Women’s Hospital. In a study published in the New England Journal of Medicine, the investigators report that genetically profiling a patient’s blood cells, while factoring in a patient’s age...

Strong results for SAA patients at Johns Hopkins

Originally Published: 02/07/2017
Physicians at the Johns Hopkins Kimmel Cancer Center report they have successfully treated 16 patients with a rare and lethal form of bone marrow failure called severe aplastic anemia using partially matched bone marrow transplants followed by two high doses of a common chemotherapy drug. In a report on the new transplant-chemo regimen, published online Dec. 22, 2016, in Biology of Blood and Marrow Transplantation, the Johns Hopkins team says that more than a year after their transplants, all of the patients have stopped taking immunosuppressive drugs commonly used to treat the disorder and...

Mayo Clinic links MDS with autoimmune drug

Originally Published: 02/03/2017
PHOENIX - Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. Researchers analyzed more than 40,000 patient cases with 27 common autoimmune diseases, such as Lupus, rheumatoid arthritis, among others, that were seen over a decade at Mayo Clinic. They identified 86 patients with therapy-related myeloid...

Medical “Must-See” TV in May

Originally Published: 02/02/2017
Near the nation’s capital, on the campus of the National Institutes of Health, sits Building 10: the largest hospital in the world devoted solely to research. Inside, our country’s most brilliant scientific minds carry out some of medicine’s riskiest and most critical research, testing new treatments in people for the very first time. With unprecedented access to the halls of Building 10, First in Human reveals for the first time how the medical breakthroughs of tomorrow make their way out of the hi-tech research laboratories and into the hands of our world’s medical professionals.  The...